Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Ipilimumab and Plinabulin in Recurrent SCLC
NCT03575793Phase 2Completed
- Start
- Sep 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of plinabulin in small cell lung cancer (SCLC) (2 arms). Primary endpoints: Maximum Tolerated Dose at 42 days and Progression-Free Survival at 9 months. Started Sep 2018; status: completed.
02
Drugs
plinabulin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03575793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575793.